Myriad Genetics Inc
NASDAQ:MYGN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15
28.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MYGN stock under the Base Case scenario is 22.15 USD. Compared to the current market price of 16.17 USD, Myriad Genetics Inc is Undervalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Myriad Genetics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MYGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Myriad Genetics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Myriad Genetics Inc
Balance Sheet Decomposition
Myriad Genetics Inc
Current Assets | 291.6m |
Cash & Short-Term Investments | 97.3m |
Receivables | 117.8m |
Other Current Assets | 76.5m |
Non-Current Assets | 793.5m |
PP&E | 172.8m |
Intangibles | 605.8m |
Other Non-Current Assets | 14.9m |
Current Liabilities | 148.9m |
Accounts Payable | 33.3m |
Accrued Liabilities | 92.6m |
Other Current Liabilities | 23m |
Non-Current Liabilities | 195.7m |
Long-Term Debt | 38.8m |
Other Non-Current Liabilities | 156.9m |
Earnings Waterfall
Myriad Genetics Inc
Revenue
|
823.6m
USD
|
Cost of Revenue
|
-254.1m
USD
|
Gross Profit
|
569.5m
USD
|
Operating Expenses
|
-664m
USD
|
Operating Income
|
-94.5m
USD
|
Other Expenses
|
-21.5m
USD
|
Net Income
|
-116m
USD
|
Free Cash Flow Analysis
Myriad Genetics Inc
USD | |
Free Cash Flow | USD |
MYGN Profitability Score
Profitability Due Diligence
Myriad Genetics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Myriad Genetics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
MYGN Solvency Score
Solvency Due Diligence
Myriad Genetics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Myriad Genetics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MYGN Price Targets Summary
Myriad Genetics Inc
According to Wall Street analysts, the average 1-year price target for MYGN is 24.28 USD with a low forecast of 14.14 USD and a high forecast of 36.75 USD.
Dividends
Current shareholder yield for MYGN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MYGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,400 full-time employees. The firm primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The firm discovers and commercializes genetic tests. The firm's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company’s wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc., Myriad Women’s Health, Inc, Myriad Genetics Espana SL, Myriad Genetics S.r.l., Myriad Genetics B.V. and Myriad Genetics GK.
Contact
IPO
Employees
Officers
The intrinsic value of one MYGN stock under the Base Case scenario is 22.15 USD.
Compared to the current market price of 16.17 USD, Myriad Genetics Inc is Undervalued by 27%.